Individualized therapy for lung cancer based on LKB1 mutations.

点击翻译按钮获取中文摘要

Individualized drug therapies based on characteristics of cancer cell are needed to improve prognoses of lung cancer patients. It has been reported that targeted agents against activated molecules responsible for cancer developments and progressions were effective in several malignant tumors including lung cancers. Mutations of the LKB1 gene and the PTEN gene that activate mTOR signaling, resulting in cell proliferations, are frequently occurred in lung cancers. In the present study, we revealed that lung cancer cells with LKB1 or PTEN mutations were more sensitive to a mTOR inhibitor than those without the mutations. Thus, it is indicated that the new individualized drug therapy based on the gene mutations might be clinically useful for lung cancers.